The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.

• Status: Completed
• Trial end date: 2020-04-01
• Target enrollment: 0
• Participant gender: All

Summary

In double-blind clinical trial, determine renal recovery with two different furosemide strategies in patients with type 1 cardiorenal syndrome.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Civil de Guadalajara
• Treatments: Chlorthalidone; Furosemide; Spironolactone

Criteria

Inclusion Criteria:

• Comply with both clinical diagnosis of acute kidney injury by serum creatinine according to the Kidney Disease Improving Global Outcomes (KDIGO) 2012 guidelines and acute decompensate heart failure as clinical assessed by the clinical team in charge.

• Have agreed and signed informed consent

Exclusion Criteria:

• Patient in chronic dialysis either peritoneal dialysis or hemodialysis.

• History of being a renal transplant recipient

• History of acute kidney injury according to the KDIGO 2012 guidelines and / or renal replacement therapy in the last 3 months

• Pregnancy

• Impossibility to administer medication by the oral route